CTKB
Cytek Biosciences, Inc.
$3.96
-1.49%
$511.4M
No data for this timeframe.
Vol
Market Cap$511.4M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (70%)
Inst. Holders50 funds
Inst. Value$203.1M
Inst. Activity9 buys / 2 sells
SEC Reports4
Recent Activity
Jun 12, 2026
SEC
Glenn P. Muir filed a Form 3 initial statement of beneficial ownership with Cytek Biosciences, Inc., indicating he has b
3 — Impact 2/10
Jun 12, 2026
short_volume
Short Volume: CTKB — 70.9% short (0.4M / 0.6M)
Short: 446,559 | Exempt: 0 | TRF Vol: 629,951 | Short Ratio: 70.9% | Off-exchange volume (dark pool
Jun 11, 2026
SEC
An institutional cluster in Cytek Biosciences (CTKB) for Q3 2025 shows mixed conviction: two passive managers added $1.4
INST-CLUSTER — Impact 5/10
Jun 10, 2026
Insider
Ball Jack acquired via exercise 43,973 shares
Director
Jun 10, 2026
Insider
MUIR GLENN P was granted 29,835 shares
Director
Jun 10, 2026
Insider
MUIR GLENN P was granted 55,555 shares
Director
Jun 2, 2026
SEC
Cytek Biosciences disclosed the resignation of Philippe Busque, Ph.D., Senior Vice President of Global Sales and Service
8-K — Impact 3/10
Inst.
Russell Investments Group, Ltd. — ADD
1,359,900 shares ($5.9M)
Price Targets
$5.69
+43.6% upside
Strong Buy
Current $3.96
Low $4.75
Median $5.25
High $7.50
4 analysts
$4.75
$7.50
Analyst Ratings
3Strong Buy
4Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 13, 2026 | Stephens & Co. | MAINTAIN | Overweight → Overweight |
| May 12, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight → Equal-Weight |
| Jan 8, 2026 | TD Cowen | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.01 ▲ +75.0% | $-0.01 — $-0.01 | -40% YoY | 1 |
| Next Q | $0.01 ▲ +166.7% | $0.01 — $0.01 | 3433% YoY | 1 |
| Current FY | $-0.04 ▲ +52.9% | $-0.04 — $-0.04 | 87% YoY | 1 |
| Next FY | $0.19 ▲ +322.2% | $0.19 — $0.19 | 575% YoY | 1 |
Latest Reports
NEUTRAL
3
2/10
Glenn P. Muir filed a Form 3 initial statement of beneficial ownership with Cytek Biosciences, Inc., indicating he has b
Jun 12, 2026
BEARISH
INST-CLUSTER
5/10
An institutional cluster in Cytek Biosciences (CTKB) for Q3 2025 shows mixed conviction: two passive managers added $1.4
Jun 11, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $74.3M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $20.8M | — |
| STATE STREET CORP | $18.0M | — |
| DIMENSIONAL FUND ADVISORS LP | $11.6M | — |
| GOLDMAN SACHS GROUP INC | $10.2M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 10, 2026 | Ball Jack | M | $0.00 |
| Jun 10, 2026 | MUIR GLENN | A | $0.00 |
| Jun 10, 2026 | MUIR GLENN | A | $0.00 |
| Jun 10, 2026 | Chin Richard | A | $0.00 |
| Jun 10, 2026 | Chin Richard | A | $0.00 |
50 institutional holders with $203.1M total value (46,476,412 shares) as of 2026-Q1. Top holders: BlackRock,, VANGUARD, STATE. Net buying activity: 9 institutions added/increased vs 2 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 17,007,269 | $74.3M | 36.6% | — |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 4,762,904 | $20.8M | 10.2% | — |
| 3 | STATE STREET CORP | 4,123,748 | $18.0M | 8.9% | — |
| 4 | DIMENSIONAL FUND ADVISORS LP | 2,663,329 | $11.6M | 5.7% | — |
| 5 | GOLDMAN SACHS GROUP INC | 2,344,735 | $10.2M | 5.0% | — |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2,311,858 | $10.1M | 5.0% | — |
| 7 | MORGAN STANLEY | 1,718,875 | $7.5M | 3.7% | ADD +27.2% |
| 8 | ROYCE & ASSOCIATES LP | 1,642,368 | $7.2M | 3.5% | ADD +26.9% |
| 9 | Russell Investments Group, Ltd. | 1,359,900 | $5.9M | 2.9% | ADD +35.8% |
| 10 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,104,601 | $4.8M | 2.4% | — |
| 11 | BANK OF AMERICA CORP /DE/ | 1,009,054 | $4.4M | 2.2% | DOUBLED +403.2% |
| 12 | VANGUARD FIDUCIARY TRUST CO | 717,011 | $3.1M | 1.5% | — |
| 13 | RENAISSANCE TECHNOLOGIES LLC | 676,700 | $3.0M | 1.5% | TRIM -25.2% |
| 14 | CITADEL ADVISORS LLC | 471,392 | $2.1M | 1.0% | NEAR_EXIT -86.7% |
| 15 | PUBLIC SECTOR PENSION INVESTMENT BOARD | 394,718 | $1.7M | 0.8% | — |
| 16 | Invesco Ltd. | 388,233 | $1.7M | 0.8% | — |
| 17 | TUDOR INVESTMENT CORP ET AL | 320,715 | $1.4M | 0.7% | — |
| 18 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 319,909 | $1.4M | 0.7% | DOUBLED +150.5% |
| 19 | FMR LLC | 283,386 | $1.2M | 0.6% | ADD +29.5% |
| 20 | D. E. Shaw & Co., Inc. | 260,125 | $1.1M | 0.6% | DOUBLED +117.4% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Russell Investments Group, Ltd. | ADD | 1,001,127 | 1,359,900 | +35.8% | $5.9M | 2026-Q1 |
| VOYA INVESTMENT MANAGEMENT LLC | ADD | 97,830 | 141,385 | +44.5% | $617.9K | 2026-Q1 |
| FRANKLIN RESOURCES INC | DOUBLED | 10,357 | 113,973 | +1000.4% | $498.1K | 2026-Q1 |
| STATE OF WISCONSIN INVESTMENT BOARD | TRIM | 168,563 | 104,046 | -38.3% | $454.7K | 2026-Q1 |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | DOUBLED | 35,725 | 72,700 | +103.5% | $260.4K | 2026-Q1 |
| FIFTH THIRD BANCORP | DOUBLED | 912 | 24,909 | +2631.3% | $108.9K | 2026-Q1 |
| Vanguard Personalized Indexing Management, LLC | ADD | 12,245 | 19,066 | +55.7% | $83.3K | 2026-Q1 |
| M&T BANK CORP | NEAR_EXIT | 42,616 | 10,308 | -75.8% | $45.0K | 2026-Q1 |
| Rockefeller Capital Management L.P. | DOUBLED | 1,026 | 5,199 | +406.7% | $22.7K | 2026-Q1 |
| GROUP ONE TRADING LLC | ADD | 1,500 | 2,200 | +46.7% | $9.6K | 2026-Q1 |
| Allworth Financial LP | ADD | 1,049 | 1,390 | +32.5% | $6.1K | 2026-Q1 |
| Russell Investments Group, Ltd. | DOUBLED | 159,513 | 1,001,127 | +527.6% | $5.1M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 170,160 | 856,161 | +403.2% | $4.3M | 2025-Q4 |
| WELLINGTON MANAGEMENT GROUP LLP | TRIM | 2,541,046 | 764,279 | -69.9% | $3.9M | 2025-Q4 |
| D. E. Shaw & Co., Inc. | DOUBLED | 121,022 | 263,126 | +117.4% | $1.3M | 2025-Q4 |
| FMR LLC | ADD | 180,786 | 234,072 | +29.5% | $1.2M | 2025-Q4 |
| AMERIPRISE FINANCIAL INC | TRIM | 328,623 | 202,316 | -38.4% | $1.0M | 2025-Q4 |
| STATE OF WISCONSIN INVESTMENT BOARD | TRIM | 338,218 | 168,563 | -50.2% | $851.2K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 90,401 | 132,675 | +46.8% | $670.0K | 2025-Q4 |
| Point72 Asset Management, L.P. | TRIM | 187,618 | 114,256 | -39.1% | $577.0K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | NEAR_EXIT | 175,759 | 30,032 | -82.9% | $151.7K | 2025-Q4 |
| State of Tennessee, Department of Treasury | TRIM | 58,883 | 22,900 | -61.1% | $114.5K | 2025-Q4 |
| Mariner, LLC | TRIM | 26,902 | 18,565 | -31.0% | $93.7K | 2025-Q4 |
| FRANKLIN RESOURCES INC | NEAR_EXIT | 86,768 | 10,357 | -88.1% | $52.3K | 2025-Q4 |
| NISA INVESTMENT ADVISORS, LLC | TRIM | 4,880 | 3,653 | -25.1% | $18.4K | 2025-Q4 |
11 unique insiders with 50 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 10, 2026 | Ball Jack | Director | EXERCISE | 43,973 | — | — |
| Jun 10, 2026 | MUIR GLENN P | Director | AWARD | 29,835 | — | — |
| Jun 10, 2026 | MUIR GLENN P | Director | AWARD | 55,555 | — | — |
| Jun 10, 2026 | Chin Richard | Director | AWARD | 18,261 | — | — |
| Jun 10, 2026 | Chin Richard | Director | AWARD | 33,333 | — | — |
| Jun 10, 2026 | Imper Vera | Director | AWARD | 18,261 | — | — |
| Jun 10, 2026 | Imper Vera | Director | AWARD | 33,333 | — | — |
| Jun 10, 2026 | Imper Vera | Director | EXERCISE | 43,973 | — | — |
| Jun 10, 2026 | NEFF DEBORAH J | Director | AWARD | 18,261 | — | — |
| Jun 10, 2026 | NEFF DEBORAH J | Director | AWARD | 33,333 | — | — |
| Jun 10, 2026 | NEFF DEBORAH J | Director | EXERCISE | 43,973 | — | — |
| Jun 10, 2026 | Holder Michael | Director | AWARD | 18,261 | — | — |
| Jun 10, 2026 | Holder Michael | Director | AWARD | 33,333 | — | — |
| Jun 10, 2026 | Holder Michael | Director | EXERCISE | 43,973 | — | — |
| May 18, 2026 | Barnett Valerie | CHIEF LEGAL OFFICER | EXERCISE | 2,454 | — | — |
| May 18, 2026 | Barnett Valerie | CHIEF LEGAL OFFICER | TAX W/H | 881 | $3.55 | $3.1K |
| May 18, 2026 | McCombe William D. | Chief Financial Officer | EXERCISE | 6,320 | — | — |
| May 18, 2026 | McCombe William D. | Chief Financial Officer | TAX W/H | 2,268 | $3.55 | $8.1K |
| May 18, 2026 | Jiang Wenbin | PRESIDENT AND CEO | EXERCISE | 7,854 | — | — |
| May 18, 2026 | Jiang Wenbin | PRESIDENT AND CEO | TAX W/H | 1,913 | $3.55 | $6.8K |
| May 18, 2026 | Busque Philippe | SVP, GLOBAL SALES AND SERVICES | EXERCISE | 1,024 | — | — |
| May 18, 2026 | Busque Philippe | SVP, GLOBAL SALES AND SERVICES | TAX W/H | 263 | $3.55 | $933.65 |
| May 18, 2026 | Yan Ming | CHIEF TECHNOLOGY OFFICER | EXERCISE | 4,908 | — | — |
| May 18, 2026 | Yan Ming | CHIEF TECHNOLOGY OFFICER | TAX W/H | 1,224 | $3.55 | $4.3K |
| May 18, 2026 | Chin Richard | Director | EXERCISE | 6,107 | — | — |
| May 18, 2026 | Holder Michael | Director | EXERCISE | 1,454 | — | — |
| Mar 13, 2026 | Yan Ming | CHIEF TECHNOLOGY OFFICER | GIFT | 1,176,000 | — | — |
| Mar 10, 2026 | Yan Ming | CHIEF TECHNOLOGY OFFICER | AWARD | 120,688 | — | — |
| Mar 10, 2026 | Yan Ming | CHIEF TECHNOLOGY OFFICER | AWARD | 227,535 | — | — |
| Mar 10, 2026 | McCombe William D. | Chief Financial Officer | TAX W/H | 2,603 | $4.23 | $11.0K |
| Mar 10, 2026 | McCombe William D. | Chief Financial Officer | EXERCISE | 6,320 | — | — |
| Mar 10, 2026 | Jiang Wenbin | PRESIDENT AND CEO | EXERCISE | 15,708 | — | — |
| Mar 10, 2026 | Jiang Wenbin | PRESIDENT AND CEO | TAX W/H | 3,825 | $4.23 | $16.2K |
| Mar 10, 2026 | Barnett Valerie | CHIEF LEGAL OFFICER | TAX W/H | 1,761 | $4.23 | $7.4K |
| Mar 10, 2026 | Jiang Wenbin | PRESIDENT AND CEO | AWARD | 485,545 | — | — |
| Mar 10, 2026 | Busque Philippe | SVP, GLOBAL SALES AND SERVICES | TAX W/H | 635 | $4.23 | $2.7K |
| Mar 10, 2026 | Chin Richard | Director | EXERCISE | 6,107 | — | — |
| Mar 10, 2026 | Holder Michael | Director | EXERCISE | 2,908 | — | — |
| Mar 10, 2026 | Busque Philippe | SVP, GLOBAL SALES AND SERVICES | AWARD | 70,665 | — | — |
| Mar 10, 2026 | Busque Philippe | SVP, GLOBAL SALES AND SERVICES | AWARD | 133,226 | — | — |
| Mar 10, 2026 | Busque Philippe | SVP, GLOBAL SALES AND SERVICES | EXERCISE | 2,049 | — | — |
| Mar 10, 2026 | McCombe William D. | Chief Financial Officer | AWARD | 256,790 | — | — |
| Mar 10, 2026 | McCombe William D. | Chief Financial Officer | AWARD | 136,205 | — | — |
| Mar 10, 2026 | Yan Ming | CHIEF TECHNOLOGY OFFICER | EXERCISE | 9,817 | — | — |
| Mar 10, 2026 | Yan Ming | CHIEF TECHNOLOGY OFFICER | TAX W/H | 3,047 | $4.23 | $12.9K |
| Mar 10, 2026 | Barnett Valerie | CHIEF LEGAL OFFICER | AWARD | 226,453 | — | — |
| Mar 10, 2026 | Barnett Valerie | CHIEF LEGAL OFFICER | EXERCISE | 4,908 | — | — |
| Mar 10, 2026 | Barnett Valerie | CHIEF LEGAL OFFICER | AWARD | 120,114 | — | — |
| Mar 10, 2026 | Jiang Wenbin | PRESIDENT AND CEO | AWARD | 915,407 | — | — |
| Feb 18, 2026 | Jiang Wenbin | PRESIDENT AND CEO | EXERCISE | 4,514 | — | — |
4 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 3 neutral. Avg impact: 3.0/10.
NEUTRAL
3
2/10
Glenn P. Muir filed a Form 3 initial statement of beneficial ownership with Cytek Biosciences, Inc.,
Jun 12, 2026
BEARISH
INST-CLUSTER
5/10
An institutional cluster in Cytek Biosciences (CTKB) for Q3 2025 shows mixed conviction: two passive
Jun 11, 2026
NEUTRAL
8-K
3/10
Cytek Biosciences disclosed the resignation of Philippe Busque, Ph.D., Senior Vice President of Glob
Jun 2, 2026
NEUTRAL
DEFA14A
2/10
Cytek Biosciences filed additional definitive proxy soliciting materials (DEFA14A) on April 28, 2026
Apr 28, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Buy (70% buy). Based on 10 analysts: 3 strong buy, 4 buy, 3 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$5.69 mean target
+43.6% upside
Strong Buy (3.00)
$4.75 Low
$7.50 High
| Metric | Value |
|---|---|
| Current Price | $3.96 |
| Target Low | $4.75 |
| Target Mean | $5.69 |
| Target Median | $5.25 |
| Target High | $7.50 |
| # Analysts | 4 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.01 | $-0.01 | $-0.01 | -40.5% | +75.0% | 0↑ 1↓ | $0.0B | 6.6% | 1 |
| Next Q 2026-09-30 |
$0.01 | $0.01 | $0.01 | 3433.3% | +166.7% | 0↑ 1↓ | $0.1B | 5.5% | 1 |
| Current FY 2026-12-31 |
$-0.04 | $-0.04 | $-0.04 | 87.2% | +52.9% | — | $0.2B | 3.6% | 1 |
| Next FY 2027-12-31 |
$0.19 | $0.19 | $0.19 | 575.0% | +322.2% | 0↑ 1↓ | $0.2B | 6.6% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.010 | |
| 7d ago | $-0.050 | +0.040 |
| 30d ago | $-0.040 | +0.030 |
| 60d ago | $-0.040 | +0.030 |
| 90d ago | $-0.015 | +0.005 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 13, 2026 | Stephens & Co. | MAINTAIN | Overweight | Overweight |
| May 12, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight | Equal-Weight |
| Jan 8, 2026 | TD Cowen | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 4 | 3 | 0 | 0 | 70% | |
| May 1, 2026 | 3 | 4 | 3 | 0 | 0 | 70% | |
| Apr 1, 2026 | 3 | 4 | 4 | 0 | 0 | 64% | |
| Mar 1, 2026 | 3 | 4 | 4 | 0 | 0 | 64% | |
| Feb 1, 2026 | 2 | 4 | 4 | 0 | 0 | 60% | |
| Jan 1, 2026 | 3 | 4 | 4 | 0 | 0 | 64% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 12, 2026
short_volume
Short Volume: CTKB — 70.9% short (0.4M / 0.6M)
Short: 446,559 | Exempt: 0 | TRF Vol: 629,951 | Short Ratio: 70.9% | Off-exchange volume (dark pool + OTC)
Jun 10, 2026
other
Cytek Biosciences to participate at the Singular Research’s Las Vegas Invitational Conference
<p>FREMONT, Calif., June 10, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today annou
Jun 2, 2026
other
Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026
At CYTO 2026, Cytek will showcase its cell analysis solutions, including the public debut of a new 7-laser Cytek Borealis full spectrum flow cytometer
May 15, 2026
short_volume
Short Volume: CTKB — 55.2% short (0.3M / 0.5M)
Short: 300,597 | Exempt: 16,745 | TRF Vol: 544,400 | Short Ratio: 55.2% | Off-exchange volume (dark pool + OTC)
May 7, 2026
earnings_calendar
CTKB Q1 2026 Earnings After Market Close — 2026-05-07
Mar 9, 2026
other
Cytek® Biosciences Celebrates One Year of Operations at Singapore Facility, Accelerating Growth and Regional Impact
Cytek Biosciences celebrates one year of operations at its Singapore facility, which has enhanced Cytek’s manufacturing capacity and regional service.
Feb 26, 2026
earnings_calendar
CTKB Q4 2025 Earnings After Market Close — 2026-02-26